Genmab A/S Files 6-K for Ongoing Reporting
Ticker: GNMSF · Form: 6-K · Filed: Aug 21, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, compliance, reporting
TL;DR
Genmab filed a 6-K, nothing new financially, just housekeeping for SEC filings.
AI Summary
Genmab A/S filed a Form 6-K on August 21, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial data but serves as an update for its ongoing reporting requirements.
Why It Matters
This filing ensures Genmab A/S remains compliant with SEC regulations by incorporating its latest report into its registration statements, which is crucial for maintaining transparency with investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new material financial information or strategic changes that would typically impact risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-012403 (filing_id) — Accession Number
- 20240821 (date) — Filing Date
- Form 6-K (document_type) — Filing Type
- Form S-8 (document_type) — Incorporated by Reference
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8, serving as part of its ongoing reporting requirements.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on August 21, 2024.
Which SEC registration statements will this 6-K filing be incorporated into?
This 6-K filing will be incorporated into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
Does this filing contain new financial results for Genmab A/S?
No, this filing is primarily for administrative purposes and incorporation by reference into existing registration statements; it does not appear to contain new financial results.
What is the principal executive office address for Genmab A/S mentioned in the filing?
The address of Genmab A/S's principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 15.8 · Accepted 2024-08-21 10:50:49
Filing Documents
- tmb-20240821x6k.htm (6-K) — 18KB
- tmb-20240821xex99d1.htm (EX-99.1) — 78KB
- tmb-20240821xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240821xex99d1003.jpg (GRAPHIC) — 1KB
- 0001558370-24-012403.txt ( ) — 105KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: August 21, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated August 19, 2024: TEPKINLY (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma